Go Pro
NASDAQ:TLPH

Talphera Q2 2026 Earnings Report

Talphera logo
$1.38 -0.09 (-5.78%)
As of 01:57 PM Eastern
Upcoming Event
Earnings Conference Call
Talphera Q2 2026
00:00 / 00:00
Live Transcript
Follow Audio

Talphera EPS Results

Actual EPS
N/A
Consensus EPS
-$0.06
Beat/Miss
N/A
One Year Ago EPS
N/A

Talphera Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Talphera Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Wednesday, August 12, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Talphera Earnings Headlines

Talphera Q2 2026 earnings preview
Talphera (NASDAQ:TLPH) Raised to Hold at Wall Street Zen
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
Talphera (TLPH) Expected to Announce Earnings on Thursday
Talphera (TLPH) CEO Angotti buys $85k in shares
See More Talphera Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Talphera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Talphera and other key companies, straight to your email.

About Talphera

Talphera (NASDAQ:TLPH), a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

View Talphera Profile